Group One Trading’s Esperion Therapeutics ESPR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $767K | Buy |
+242,645
| New | +$679K | ﹤0.01% | 3133 |
|
|
2025
Q4 | – | Sell |
-162,589
| Closed | -$525K | – | 8405 |
|
|
2025
Q3 | $431K | Sell |
162,589
-65,536
| -29% | -$127K | ﹤0.01% | 3850 |
|
|
2025
Q2 | $225K | Buy |
228,125
+78,404
| +52% | +$78.5K | ﹤0.01% | 4219 |
|
|
2025
Q1 | $216K | Buy |
149,721
+52,587
| +54% | +$96.9K | ﹤0.01% | 3949 |
|
|
2024
Q4 | $214K | Sell |
97,134
-86,517
| -47% | -$202K | ﹤0.01% | 3890 |
|
|
2024
Q3 | $303K | Buy |
183,651
+166,198
| +952% | +$336K | ﹤0.01% | 3261 |
|
|
2024
Q2 | $38.7K | Sell |
17,453
-103,306
| -86% | -$243K | ﹤0.01% | 4720 |
|
|
2024
Q1 | $324K | Buy |
+120,759
| New | +$293K | ﹤0.01% | 3146 |
|
|
2023
Q4 | – | Sell |
-310,778
| Closed | -$403K | – | 7585 |
|
|
2023
Q3 | $305K | Sell |
310,778
-11,028
| -3% | -$16K | ﹤0.01% | 3423 |
|
|
2023
Q2 | $447K | Sell |
321,806
-25,104
| -7% | -$35.1K | ﹤0.01% | 3133 |
|
|
2023
Q1 | $552K | Buy |
346,910
+85,559
| +33% | +$442K | ﹤0.01% | 2681 |
|
|
2022
Q4 | $1.63M | Buy |
+261,351
| New | +$1.87M | ﹤0.01% | 2010 |
|
|
2021
Q4 | – | Sell |
-15,754
| Closed | -$126K | – | 8355 |
|
|
2021
Q3 | $190K | Sell |
15,754
-3,945
| -20% | -$57.4K | ﹤0.01% | 5229 |
|
|
2021
Q2 | $417K | Buy |
19,699
+8,057
| +69% | +$194K | ﹤0.01% | 4424 |
|
|
2021
Q1 | $327K | Buy |
+11,642
| New | +$343K | ﹤0.01% | 4498 |
|
|
2019
Q3 | – | Sell |
-12,078
| Closed | -$478K | – | 5252 |
|
|
2019
Q2 | $562K | Buy |
12,078
+978
| +9% | +$45.9K | 0.01% | 2036 |
|
|
2019
Q1 | $446K | Buy |
11,100
+7,810
| +237% | +$350K | 0.01% | 2037 |
|
|
2018
Q4 | $151K | Sell |
3,290
-5,893
| -64% | -$284K | ﹤0.01% | 2890 |
|
|
2018
Q3 | $407K | Sell |
9,183
-28,708
| -76% | -$1.32M | ﹤0.01% | 2454 |
|
|
2018
Q2 | $1.49M | Buy |
37,891
+18,063
| +91% | +$913K | 0.01% | 1347 |
|
|
2018
Q1 | $1.43M | Buy |
19,828
+14,987
| +310% | +$1.1M | 0.01% | 1235 |
|
|
2017
Q4 | $319K | Buy |
+4,841
| New | +$261K | ﹤0.01% | 2604 |
|
|
2017
Q3 | – | Sell |
-10,810
| Closed | -$521K | – | 4908 |
|
|
2017
Q2 | $500K | Sell |
10,810
-47,502
| -81% | -$1.75M | 0.01% | 1967 |
|
|
2017
Q1 | $2.06M | Buy |
58,312
+53,620
| +1,143% | +$1.23M | 0.02% | 848 |
|
|
2016
Q4 | $59K | Buy |
+4,692
| New | +$55.9K | ﹤0.01% | 3160 |
|
|
2016
Q3 | – | Sell |
-1,182
| Closed | -$13.4K | – | 4631 |
|
|
2016
Q2 | $12K | Sell |
1,182
-9,393
| -89% | -$156K | ﹤0.01% | 4004 |
|
|
2016
Q1 | $179K | Buy |
+10,575
| New | +$170K | ﹤0.01% | 2399 |
|
|
2015
Q4 | – | Sell |
-14,248
| Closed | -$359K | – | 4826 |
|
|
2015
Q3 | $336K | Buy |
+14,248
| New | +$894K | ﹤0.01% | 2101 |
|
|
2015
Q2 | – | Sell |
-21,484
| Closed | -$2.1M | – | 4926 |
|
|
2015
Q1 | $1.99M | Buy |
21,484
+14,384
| +203% | +$928K | 0.03% | 642 |
|
|
2014
Q4 | $287K | Buy |
+7,100
| New | +$217K | ﹤0.01% | 2000 |
|
Other funds holding ESPR
GCL
TC
AA
OBAM
Group One Trading's ESPR Position: Q2 2026 in Review
Group One Trading opened a new position in Esperion Therapeutics (ESPR) in Q2 2026: 242,645 shares worth $767K. The stake represents ﹤0.01% of the portfolio and ranks #3133 among its holdings. This is a return to the name: Group One Trading previously reported a position in ESPR as recently as Q3 2025.
Group One Trading first reported a position in ESPR in Q4 2014 and has held it in 30 quarters since. The position peaked at $2.06M in Q1 2017. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.
- Group One Trading held 242,645 shares of Esperion Therapeutics worth $767K as of Q2 2026.
- Esperion Therapeutics was a new Group One Trading position in Q2 2026.
- Esperion Therapeutics made up ﹤0.01% of Group One Trading's portfolio in Q2 2026, its #3133 holding.
- Group One Trading first reported a position in Esperion Therapeutics in Q4 2014 and has held it in 30 quarters since.
- Group One Trading's Esperion Therapeutics position peaked at $2.06M in Q1 2017.
- 191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.
Based on Group One Trading's 13F filing for Q2 2026, filed 14 Aug 2026.